Latest Report 'How to Integrate Personalized Medicine into Business Strategies' Provides Perspectives From Pharmaceutical, Diagnostic, and Managed Care Executives
Posted on: Thursday, 6 November 2008, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/research/f3db4d/how_to_integrate_p) has announced the addition of Decision Resources, Inc.'s new report "How to Integrate Personalized Medicine into Business Strategies" to their offering.
A growing awareness is taking hold across the pharmaceutical industry: what was once impossible -- tailoring treatment to specific groups of patients rather than to the population as a whole -- is becoming possible. What is needed to integrate a personalized medicine approach into business strategies? We provide perspectives from pharmaceutical, diagnostic, and managed care executives and create a set of recommendations based on what experts advise when contemplating the operational shift to the delivery of personalized healthcare.
Get the Answers You Need to Shape Your Strategy
- Lilly has said it needs to transform every part of its operations. How is Lilly working to integrate a personalized medicine approach into its business strategies? What is entailed in the company's cultural and organizational restructuring and its new FIPNet model?
- Roche completed a hostile takeover of Ventana and announced its intention to assume complete control of Genentech. Why are these two strategic maneuvers so important to Roche and why are they important to integrating personalized medicine strategies more tightly into the company's operations? Does personalized medicine success require that a company consume its diagnostic or targeted therapy partner outright and own it lock, stock, and barrel?
- The pharmaceutical industry has adopted formularies and benefit plan designs to differentiate drugs. What are the problems covering and reimbursing genetic testing and pharmacodiagnostic tests? What problems continue to plague gene-based testing and value-added reimbursement?
Scope
- Business models and strategies: FIPNet, outsourcing, precompetitive collaboration, personalized medicine, fully integrated pharmaceutical company (FIPCO), virtual companies, nichebusters, operational efficiencies, cost-cutting, mega-mergers, consolidation, control versus ownership, decentralized management, hub and spoke business.
- Diagnostic issues: Trends in genetic tests and genetic testing, improving the predictability of biomarker discovery, standardizing biomarkers, analytic validity, clinical utility, clinical validity, integrating diagnostic development into clinical development, fluorescence imaging, molecular diagnostics, gene profiling, biological signatures, tissue-based diagnostics.
- Pharmaceutical issues: Tailored therapies, disease biology areas, deal making, innovation, information flow and unfettered access to research, nichebusters, patient phenotypes, health outcomes, value-for-money.
- RxDx partnership issues: Adequate control of intellectual property, structuring the relationship, structuring the deal, what to look for in a diagnostic partner.
- Managed care issues: Value-added reimbursement, revamping CPT codes, cost-containment, evidentiary-based review, health policy technology assessments, physician and patient education strategies, direct-to-consumer marketing.
- Two Spectrum, Personalized Medicine Scorecards: Executive insights from transcripts of Lilly and Roche company presentations to investors.
- Expert commentaries: Executives from Iris BioTechnologies, Roche, and VisEn Medical share their insights on genetic tests, targeted therapies, personalized medicine development, transitioning from research to the clinic, and healthcare coverage and reimbursement.
- Interviews: Senior directors from two health benefit insurers share their insights on genetic and pharmacogenomic tests, evidence-based review, coding, and reimbursement issues.
Some of the Companies mentioned:
- 454 Life Sciences
- Abbott
- Affymetrix
- Agendia
- Alnylam Pharmaceuticals
- American College of Obstetricians/Gynecologists
- American Diabetes Association
- American Medical Association
- Amgen
- Arius Research
- Aveo Pharmaceuticals
- Biosite
- BioVeris
- Blue Cross Blue Shield
- Daiichi Sankyo
- Eli Lilly and Company
- GE Healthcare
- Genentech
- Genomic Health
- HealthLeaders InterStudy
- Hoffmann-La Roche
- Iris BioTechnologies
- Johnson & Johnson
- Merck & Co.
- Mirus Bio
- NimbleGen Systems
- Pfizer
- PureTech Ventures
- Roche Diagnostics
- Roche Group
- Roche Pharmaceuticals
- Therapeutic Human Polyclonals
- VisEn Medical
- WellPoint Health Networks
For more information visit http://www.researchandmarkets.com/research/f3db4d/how_to_integrate_p
Source: Business Wire
Related Articles
- Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told
- LUMEN 2009 Brings in Top Guns of Cardiac Medicine to Address America's Number One Health Issue
- The Coriell Institute for Medical Research Selects Affymetrix SNP Array 6.0 for Delaware Valley Personalized Medicine Project
- Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
- Personalized Medicine Coalition Announces Support for Secretary Leavitt's Personalized Health Care Initiative
- Analyze Americans' Attitudes Toward Pharmacogenomics and Personalized Medicine
- Pharmaceutical and Biotechnology Companies Are Turning to Personalized Medicine to Help Improve the Drug Development Process and Speed the Approval of New Drugs
- Harvard - Partners Center for Genetics and Genomics Hosts Personalized Medicine Conference; Dr. Eric Topol of the Cleveland Clinic and Dr. David Brailer of HHS Join Program of Thought Leaders to Analyze Opportunities for Transforming Healthcare
- Research and Markets: Shift Toward 'Personalized Medicine' is Helping the Drug Industry to Achieve the Goal of Cost-Effective and Faster Research
 |
 |
User Comments (0)
RSS Feeds